Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB07010 + trivalent influenza vaccine
- Development stage
- Unknown
- Lead developer
- Advagene
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
DCB07010 + trivalent influenza vaccine is an investigational intranasal vaccine candidate developed by Advagene Biopharma. It consists of trivalent inactivated influenza virus hemagglutinin (HA) antigens co-administered with DCB07010, a proprietary protein-based adjuvant. DCB07010 is derived from a prokaryotic organism, specifically a modified version of the heat-labile enterotoxin (LT) from *Escherichia coli*. This combination is designed to enhance both mucosal (secretory IgA) and systemic (IgG) immune responses against seasonal influenza. By utilizing the intranasal route, the vaccine aims to provide a needle-free alternative that stimulates immunity at the primary site of viral entry. The product has been evaluated in Phase 1 clinical trials to assess safety, tolerability, and immunogenicity in healthy adults.
- Other names
- DCB07010 adjuvant with influenza vaccineDCB-07010 adjuvant with influenza vaccineDCB 07010 adjuvant with influenza vaccineDCB07010 + TIV
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on DCB07010 + trivalent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCB07010 + trivalent influenza vaccine.